FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892279738> ?p ?o ?g. }

• W2892279738 abstract "e23013 Background: The efficacy of the metronomic use of conventional chemotherapeutic drugs in the clinic has been linked to their anti-angiogenic activity. However, the dose level for the metronomic use of the drugs with regard to anti-angiogenic activity is not known. In the current study, we aimed to study the effects of very low doses of 5-florouracil (5-FU), irinotecan and oxaliplatin on the synthesis of pro-angiogenic factors in tumor cells. Methods: We first determined the IC50 doses of 5-FU, irinotecan, and oxaliplatin in human tumor cell lines (HT-29: colon cancer cells, MCF-7: breast cancer cells and LNCaP: prostatic carcinoma cells). Then we applied the drugs to the assigned cells at the dose levels of IC50, -1log, -2log and -3log of IC50. The effects of the drugs on both gene expression and protein secretion levels of pro-angiogenic genes including vascular endothelial growth factor A (VEGF-A), basic-fibroblast growth factor (bFGF), matrix metalloproteinase-9 (MMP-9), platelet-derived growth factor-beta (PDGF-B), interleukin-8 (IL-8) and factor secretion by real-time PCR and sandwich ELISA. Results: The IC50 levels of 5-FU, irinotecan, and oxaliplatin in tumor cells were found as shown in the Table. We found that -1logIC50 dose level of 5-FU efficiently suppressed the pro-angiogenic genes both at the gene expression and protein secretion levels. However, the -2logIC50 and -3logIC50 dose levels of both irinotecan and oxaliplatin significantly inhibited gene expression and protein secretion. Conclusions: In conclusion, our results suggest that irinotecan and oxaliplatin could be used as anti-angiogenic agents at the very low doses. The -1logIC50 dose for 5-FU and the -2log and -3logIC50 doses of irinotecan and oxaliplatin could be further tested in animal models and clinical trials. Table. The IC50 dose levels of the drugs in tumor cell lines. [Table: see text]" @default.
• W2892279738 created "2018-09-27" @default.
• W2892279738 creator A5012861159 @default.
• W2892279738 creator A5038092087 @default.
• W2892279738 creator A5050692662 @default.
• W2892279738 creator A5060378855 @default.
• W2892279738 creator A5061917722 @default.
• W2892279738 creator A5088040670 @default.
• W2892279738 date "2017-05-20" @default.
• W2892279738 modified "2023-09-25" @default.
• W2892279738 title "Effect of very low doses of chemotherapeutic drugs on proangiogenic factors in tumor cells." @default.
• W2892279738 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23013" @default.
• W2892279738 hasPublicationYear "2017" @default.
• W2892279738 type Work @default.
• W2892279738 sameAs 2892279738 @default.
• W2892279738 citedByCount "0" @default.
• W2892279738 crossrefType "journal-article" @default.
• W2892279738 hasAuthorship W2892279738A5012861159 @default.
• W2892279738 hasAuthorship W2892279738A5038092087 @default.
• W2892279738 hasAuthorship W2892279738A5050692662 @default.
• W2892279738 hasAuthorship W2892279738A5060378855 @default.
• W2892279738 hasAuthorship W2892279738A5061917722 @default.
• W2892279738 hasAuthorship W2892279738A5088040670 @default.
• W2892279738 hasConcept C126322002 @default.
• W2892279738 hasConcept C2776694085 @default.
• W2892279738 hasConcept C3020391286 @default.
• W2892279738 hasConcept C502942594 @default.
• W2892279738 hasConcept C71924100 @default.
• W2892279738 hasConcept C98274493 @default.
• W2892279738 hasConceptScore W2892279738C126322002 @default.
• W2892279738 hasConceptScore W2892279738C2776694085 @default.
• W2892279738 hasConceptScore W2892279738C3020391286 @default.
• W2892279738 hasConceptScore W2892279738C502942594 @default.
• W2892279738 hasConceptScore W2892279738C71924100 @default.
• W2892279738 hasConceptScore W2892279738C98274493 @default.
• W2892279738 hasLocation W28922797381 @default.
• W2892279738 hasOpenAccess W2892279738 @default.
• W2892279738 hasPrimaryLocation W28922797381 @default.
• W2892279738 hasRelatedWork W1989663897 @default.
• W2892279738 hasRelatedWork W2022662750 @default.
• W2892279738 hasRelatedWork W2028665955 @default.
• W2892279738 hasRelatedWork W2084122259 @default.
• W2892279738 hasRelatedWork W2091496169 @default.
• W2892279738 hasRelatedWork W2112281786 @default.
• W2892279738 hasRelatedWork W2169965478 @default.
• W2892279738 hasRelatedWork W2367882767 @default.
• W2892279738 hasRelatedWork W2565484157 @default.
• W2892279738 hasRelatedWork W2591243366 @default.
• W2892279738 hasRelatedWork W2746906250 @default.
• W2892279738 hasRelatedWork W2784964219 @default.
• W2892279738 hasRelatedWork W2790541566 @default.
• W2892279738 hasRelatedWork W2890217657 @default.
• W2892279738 hasRelatedWork W2907518195 @default.
• W2892279738 hasRelatedWork W3046370619 @default.
• W2892279738 hasRelatedWork W46091236 @default.
• W2892279738 hasRelatedWork W49808364 @default.
• W2892279738 hasRelatedWork W64035185 @default.
• W2892279738 hasRelatedWork W945092805 @default.
• W2892279738 isParatext "false" @default.
• W2892279738 isRetracted "false" @default.
• W2892279738 magId "2892279738" @default.
• W2892279738 workType "article" @default.